Document:

Exhibit 10.25

 

Non-Competition
Agreement

 

No.
201903001

 

Party
A (Employer): Xynomic Pharmaceuticals (Zhongshan) Co., Ltd.

Legal
Representative: Xu Yinglin

 

Party
B (Employee): Zhao Bing

ID
Number:                                           

 

WHEREAS,

 

1.
The Employee has access to and knowledge of the business secrets of the Company and its affiliates during its work at the Company;

 

2.
The Employee construes and acknowledges that its engagement in a job involving the Company’s competing business upon leaving
the Company would seriously damage the economic benefits of the Company and its affiliates or put the Company and its affiliates
in a very disadvantageous position in competition;

 

NOW
THEREFORE, the two parties hereto make and enter into this Agreement on the basis of voluntary, equal and consensual consultations
in accordance with relevant laws and regulations of the People’s Republic of China and the place where the Company is located
for joint observance.

 

Article
1 Competition Prohibition 

 

Without
Party A’s prior written consent, Party B shall not engage in the following activities during its term of office;

 

1.
Run alone, or participate in running a unit that has a competitive relationship with Party A or Party A’s affiliates in
business;

 

2.
Operate alone, participate in operating, or operate for others the businesses (including investment) of the same kind as those
of Party A and Party A’s affiliates;

 

    1

     

    

 

3.
Operate alone, participate in operating, or operate for others the products of the same kind as those produced or operated by
Party A and Party A’s affiliates;

 

4.
Operate alone, participate in operating, or operate for others the products or services relating to the business secrets of Party
A and Party A’s affiliates;

 

5.
Rally, induce, recruit, agitate or poach, directly or indirectly, alone or together with others, Party A’s other members
to leave office for the interests of the Employee itself, others or any entity.

 

Article
2 Competition Restriction

 

1.
The term of competition restriction is the 24 months from the termination or rescission of the Labor Contract (regardless
of the reason for termination or rescission) by either the Employee or the Employer, during which the Employee shall not work
or serve in any competitive employer that produces or operates the same kind of products or engages in the same kind of businesses
as the Unit, or produce or operate the same kind of products or engage in the same kind of businesses alone.

 

2.
The Employee with the competition restriction obligation shall not work or serve in the following units:

 

(1)
A unit that has a competitive relationship with the Company in business (including but not limited to the units specified in Annex
1 to the Agreement);

 

(2)
A company, enterprise, R&D organization, advisory or survey institution, or any economic organization directly or indirectly
established, shared, held, or actually controlled by a competitive unit of the Company in the People’s Republic of China
or in any other place where an affiliate of the Company is located;

 

(3)
Other units engaging in the business competing with that of the Company.

 

3.
The Employee with the competition restriction obligation shall not have the following acts:

 

(1)
Having business contacts with any client of the Company. Such business contacts include providing it with information or services,
receiving orders from it, directly or indirectly transferring the Company’s business to it, and any other acts that may
have or are likely to have an adverse impact on the Company’s businesses, whether being benefited or not;

 

    2

     

    

 

(2)
Directly or indirectly having shares or interests in, or accepting services or obtaining benefits from any of the units specified
in Article 2 hereof;

 

(3)
The Employee itself or together with others directly participating in the production or operation of same kind of products or
businesses competing with those of the Company;

 

(4)
Directly or indirectly hiring, or inducing, requiring, persuading or encouraging resignation of other employees of the Company,
or attempting to induce, require, persuade or encourage resignation of, or hire or take with it other employees of the Company,
for whatever reason or no reason, whether for its own benefits or for the benefits of any other person or organization; encouraging
or inducing, in its own name or in the name of any third party, any employee of the Company to serve in other units;

 

(5)
Directly or indirectly providing any form of advisory services, contracts or labor services to any unit competing with the Company.

 

4.
Regardless of the reason for the Employee’s departure from the Company, the Employee shall provide a written statement of
the name, nature and main businesses of the new employer to the Company prior to working in this new employer.

 

Article
3 Performance and Release of Obligations

 

1.
The Employee shall have the competition prohibition obligation during its employment. The Employer shall bear the competition
restriction obligation forthwith upon its departure from the Company, but the Company may notify in writing the Employee of releasing
its competition restriction obligation prior to or upon its departure from the Company; the competition restriction obligation
agreed in shall be released from the date specified in the foregoing notice and the Company shall simultaneously cease to pay
compensations for competition restriction.

 

2.
In case that the Employee fully performs its competition restriction obligation and the Company fails to pay compensations for
competition restriction agreed herein for a period of more than three months, the Employee may terminate the competition restriction
agreement in accordance with the law. Should any dispute arise between the two parties hereto over the compensation for competition
restriction, the Employee shall continue to perform its competition restriction obligation during the period of settling the dispute.

 

    3

     

    

 

Article
4 Economic Compensation for Competition Restriction

 

1.
Regardless of the circumstances under which the labor relations with the Company was terminated or rescinded, the Employee with
the competition restriction obligation shall strictly comply with provisions relating to competition restriction hereunder and
fulfill the competition restriction obligation during the compensation restriction period, and the Company shall compensate the
Employee for competition restriction.

 

2.
The compensation for competition restriction shall be 30% of the Employee’s average salary of the twelve months prior
to the termination or rescission of the Labor Contract. The Company shall pay such compensations on a monthly basis and withhold
and remit the individual income tax.

 

3.
The Employee shall deliver personally or send by a registered mail the proof of performing the competition restriction obligation
to the Company on the first month of every quarter. Such proof shall include but not be limited to the documentation from the
unit where the Employee works and the Employee’s written commitment to perform the competition restriction obligation.

 

4.
The Employee shall provide its own bank account in writing to the Company prior to its departure from the Company for the Company’s
payment of compensations for competition restriction. In case that the Employee didn’t provide its bank account, or provided
a wrong or a cancelled bank account, causing the Company’s failure to pay such compensations for competition restructure,
the Employee shall bear the resulting losses independently and shall not be exempted from its competition restriction obligation
during the corresponding period.

 

5.
In case that the Employee rejects to accept, voluntarily waives, or does not receive such compensations for competition restriction,
or the Company fails to pay such compensations for competition restriction on schedule for reasons of the Employee, the Employee
shall bear the resulting losses independently and shall not be exempted from its competition restriction obligation.

 

    4

     

    

 

6.
Should the standard for competition restriction compensation agreed herein be lower than the minimum standard imposed by the government
in the place where the Company is located, the Company shall make up the compensation to meet the minimum standard prior to the
expiration of the competition restriction, and prior to this, the Employee shall continue to perform its competition restriction
obligation.

 

Article
5 Liability for Breach of Contract

 

Party
A and Party B mutually agree:

 

1.
Should Party B violate the competition prohibition obligation during its term of office or violate the competition restriction
obligation during the validity of the Agreement, whether any economic losses are caused thereupon, Party A may terminate the Labor
Contract with Party B and require Party B to compensate it for the economic losses (if have) caused to it and pay RMB100,000 to
it as the liquidated damage (one hundred thousand yuan in total); and may hold Party B criminally liable when the circumstance
constitutes a crime.

 

2.
Should Party B’s breach of contract as stated in the preceding paragraph cause any losses to Party A or any third party,
Party B shall also bear the corresponding liability for compensating the actual losses.

 

3.
The reasonable fees paid by Party A for investigating Party B’s breach of contract (including reasonable fees and expenses
for attorneys and consultants) shall be incorporated in the amount of damages payable.

 

4.
Upon Party B’s assumption of damages and other civil liabilities as agreed herein, Party A shall still reserve the right
to request holding Party B criminally and administratively liable through judicial channels.

 

    5

     

    

 

Article
6 Dispute Settlement

 

Any
dispute arising from the performance of the Agreement shall be settled by the two parties hereto through consultations. Should
the dispute fail to be settled through consultations, the two parties hereto agree to bring the case to a people’s court
in the place where the Agreement is signed.

 

Article
7 Validity and Modification of the Agreement

 

This
Agreement comes into force upon being signed by the two parties hereto. Any modification of the Agreement shall be agreed in writing
by the two parties hereto in advance.

 

Article
8 Miscellaneous

 

This
Agreement is made in duplicate, and each party holds one with the same legal effects.

 

(No
Body Text Below)

 

	Party A:	Party B:

 

Authorized
Representative:

 

	Date:	Date:

 

Place
of Signing: Xuhui District, Shanghai, China

 

    6

     

    

 

Annex
1

 

List
of Units Competing with the Company in Business (including but not Limited to the following companies):

 

	Serial No.	 	Unit Name	 	Notes
	1	 	BeiGene	 	The parent company and all its subsidiaries inside and outside China
	2	 	Zai Lab Limited	 	The parent company and all its subsidiaries inside and outside China
	3	 	Shanghai Hutchison Pharmaceuticals	 	The parent company and all its subsidiaries inside and outside China
	4	 	CStone Pharmaceuticals	 	The parent company and all its subsidiaries inside and outside China
	5	 	EOC Pharma Group	 	The parent company and all its subsidiaries inside and outside China

 

 

7Exhibit 10.1

 

BILL OF SALE, TRANSFER, ASSIGNMENT,
AND HOLD HARMLESS

 

This BILL OF
SALE, TRANSFER, ASSIGNMENT, AND HOLD-HARMLESS ASSIGNMENT (“Assignment”), dated as of April 14, 2019, is made
by and among Solei Systems, Inc., a Florida corporation and its wholly-owned subsidiary, CareClix, Inc., a Virginia corporation(collectively
“SOLI”), and KB Medical Systems, LLC., a limited liability company (“Seller”)  

 

RECITALS

 

WHEREAS, SOLI
and Seller previously entered into an Acquisition Agreement dated as of February 18, 2019 (the “Agreement”) under which
Seller agreed to transfer all of the assets of Seller to SOLI free of all claims, debts and liabilities, and as set forth on Schedule
“A” hereto (the “Assets”); and

 

WHEREAS, SOLI
and Seller have determined that it is in the best interests of their respective corporations and stockholders, and members that
the Assets be transferred to SOLI under the Agreement;

 

NOW, THEREFORE,
in consideration of the foregoing, the receipt by Seller of the consideration for the Assets as set forth in the Agreement and
herein, and of the representations, warranties, covenants and Assignment contained herein, the parties hereto hereby agree as follows:

 

Section 1.
 A TRANSFER OF Assets.
Seller hereby transfers, conveys, and assigns to CareClix, Inc. all of the ownership of and rights to the Assets of
Buyer, as listed on Schedule A attached hereto, free and clear of any and all liabilities, claims, debts, taxes, actions, or causes
of action existing, relating to or arising out of the Assets of Seller; and SOLI hereby accepts and assumes ownership of the Assets
in exchange for the consideration delivered to Seller as set forth in the Agreement.

 

B. CONSIDERATION.
The total Consideration for the transfer of the Assets to CareClix, Inc. shall be $2,000,000, payable as follows:

 

		1.	Cash consideration of $1,000,000 to be transferred by SOLI to Seller
by wire transfer to the account of Seller as designated by Seller which wire transfer shall be requested immediately upon execution
and delivery of this transfer and assignment by Seller; and

		2.	Unregistered, restricted common shares of Solei Systems, Inc. (“Shares”)
having a market value at the date of issue of $1,000,000 based on the five (5) day trailing average closing market bid price for
the common stock of Solei Systems, Inc. on the trading market on which such shares are then traded, on the date which is six (6)
months after the date of Closing.

		3.	Closing of the transaction contemplated herein shall be on the date
of execution by Seller and the approval of all of the members of Seller and the transfer and assignment of the Assets shall be
effective on such date, notwithstanding the deferred delivery of the Shares to Seller as herein provided.

 

Section
2.   NOTICES.  Any notice required to be given hereunder shall be sufficient if in writing, and
sent by courier service (with proof of service), hand delivery, certified or registered mail (return receipt requested and first-class
postage prepaid) or electronic mail (with electronic confirmation of delivery), addressed as follows:

 

(a) if to SOLI: 

Solei Systems, Inc.

206 N. Washington Street

Suite 100

Alexandria, VA 22134 

     1

     

    

  (b) if to Seller

 

KB Medical Systems, LLC

1900 K Street, NW

Suite 5R

Washington, DC 20006

 

or to such other address as any
party shall specify by written notice so given, and such notice shall be deemed to have been delivered as of the date so telecommunicated,
personally delivered, emailed or mailed.

 

Section 3  
ASSIGNMENT; BINDING EFFECT.  This Assignment shall be binding upon and shall inure to the benefit of the parties
hereto and their respective successors and assigns effective as of and on the date of Closing, as herein defined.

 

Section 4  ENTIRE
AGREEMENT; NO THIRD PARTY BENEFICIARIES; NO OTHER REPRESENTATIONS AND WARRANTIES.

 

(a) This
Assignment, the Agreement and any documents delivered by the parties in connection herewith constitute the entire agreement among
the parties with respect to the subject matter hereof and supersede all other agreements and understandings among the parties with
respect thereto. No addition to or modification of any provision of this Assignment shall be binding upon any party hereto unless
made in writing and signed by all parties hereto.

 

(b) This
Assignment and any documents delivered by the parties in connection herewith are not intended to confer upon any person other than
the parties any rights or remedies other than the right of SOLI, on its own behalf and on behalf of its shareholders, subsidiaries,
officers and directors, to pursue damages and other relief, including equitable relief, in the event of Seller’s breach of
any of itsr covenants and undertakings in the Agreement and in this Assignment,

 

Section 5.  COUNTERPARTS.  This
Assignment may be executed in several counterparts, each of which shall be deemed to be an original, but all of which together
shall be deemed to be one and the same instrument. Signatures delivered by facsimile or other electronic means shall be deemed
originals for all purposes.

 

Section 6.  HEADINGS.  Headings
of the Articles and Sections of this Assignment are for the convenience of the parties only, and shall be given no substantive
or interpretative effect whatsoever.

 

Section 7.  SEVERABILITY.  Any
term or provision of this Assignment which is invalid or unenforceable in any jurisdiction shall, as to that jurisdiction, be ineffective
to the extent of such invalidity or unenforceability without rendering invalid or unenforceable the remaining terms and provisions
of this Assignment or affecting the validity or enforceability of any of the terms or provisions of this Assignment in any other
jurisdiction. If any provision of this Assignment is so broad as to be unenforceable, the provision shall be interpreted to be
only so broad as is enforceable.

 

     2

     

    

IN WITNESS
WHEREOF, the parties have executed this Assignment and caused the same to be duly delivered on their behalf on the day and year
first written above.

 

Solei Systems,
INC.

 

 

BY:__/s/________________________

NAME: JOSH FLOOD

ITS: PRESIDENT

 

 

KB MEDICAL SYSTEMS, LLC

 

 

BY:___/s/______________________

NAME: SHAHIN JOHN KORANGY

ITS: MANAGING MEMBER

 

 

     3

     

    

 

Schedule ‘A’

 

 

Assets being transferred (the “Assets”) includes
the use of the name CareClix and all related trademark, services marks and trade names and registrations.

 

The Assets shall include all of the assets listed or
described on the Balance Sheet of Seller dated March 31, 2019, attached hereto and incorporated herein.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00294-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00294-of-00352.parquet"}]]